Home » Stocks » IntelGenx Technologies

IntelGenx Technologies Corporation (IGXT)

Stock Price: $0.208 USD 0.000 (0.00%)
Updated Jul 31, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 22.93M
Revenue (ttm) 528,000
Net Income (ttm) -10.53M
Shares Out 110.26M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $0.208
Previous Close $0.208
Change ($) 0.000
Change (%) 0.00%
Day's Open 0.210
Day's Range 0.204 - 0.210
Day's Volume 142,726
52-Week Range 0.115 - 0.700

More Stats

Market Cap 22.93M
Enterprise Value 26.68M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 110.26M
Float 109.05M
EPS (basic) -0.12
EPS (diluted) -0.11
FCF / Share -0.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 2.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 43.44
PB Ratio 8.45
Revenue 528,000
Operating Income -9.38M
Net Income -10.53M
Free Cash Flow -8.49M
Net Cash -3.75M
Net Cash / Share -0.03
Gross Margin 140.53%
Operating Margin -1,776.89%
Profit Margin -1,994.10%
FCF Margin -1,607.20%
ROA -37.79%
ROE -200.25%
ROIC -65.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$0.61*
Low
0.61
Current: $0.208
High
0.61
Target: 0.61
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.741.825.205.225.101.660.951.200.430.95
Revenue Growth-59.32%-64.89%-0.48%2.45%207.11%75%-20.87%176.67%-54.32%-
Gross Profit0.741.824.824.904.661.600.951.200.430.95
Operating Income-9.55-9.00-2.49-0.981.39-1.78-1.64-2.26-2.45-3.39
Net Income-10.66-10.11-3.05-1.181.29-1.75-1.64-2.25-2.45-3.10
Shares Outstanding93.5374.1266.1563.9663.5263.1854.0249.6443.7435.33
Earnings Per Share-0.11-0.14-0.04-0.020.01-0.03-0.03-0.04-0.05-0.08
Operating Cash Flow-8.20-8.53-4.381.730.55-1.38-1.17-1.64-2.32-2.77
Capital Expenditures-0.53-1.10-0.97-2.33-3.38-0.40-0.27-0.27-0.16-0.04
Free Cash Flow-8.72-9.63-5.36-0.60-2.83-1.78-1.44-1.91-2.48-2.81
Cash & Equivalents1.9111.004.904.502.874.405.012.063.591.14
Total Debt8.798.008.013.311.76-----
Net Cash / Debt-6.872.99-3.111.181.114.405.012.063.591.14
Assets11.0220.0213.1512.798.926.286.224.164.571.83
Liabilities10.7310.039.327.853.351.711.211.980.670.35
Book Value0.299.993.834.955.564.575.012.183.901.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IntelGenx Technologies Corporation
Country Canada
Employees 48
CEO Horst G. Zerbe

Stock Information

Ticker Symbol IGXT
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: IGXT

Description

IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral thin film products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, and INT0040/2014. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Insud Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.